A Study to Assess the Systemic Pharmacokinetics, Metabolism and Excretion Routes of YM178 in Man, After Administration of Radio-labeled YM178

• ClinicalTrials.gov Identifier: NCT01651312
• Recruitment Status: Completed
• First Posted: July 27, 2012
• Last Update Posted: September 5, 2013
• Sponsor: Astellas Pharma Europe B.V.
• Information provided by (Responsible Party): Astellas Pharma Inc ( Astellas Pharma Europe B.V. )

Study Description

Brief Summary:

The study aims to assess the routes and the extent of metabolism and excretion of YM178 after a single dose of 14C-radiolabeled YM178 administered as a drinking solution in healthy male volunteers.

Condition or disease	Intervention/treatment	Phase
Metabolic Processes	Drug: 14C-labeled YM178	Phase 1

Detailed Description:

Four subjects are studied in one group. Each subject stays in the clinic for 6 days, and receives a single oral dose of 14C-labeled YM178. Blood, plasma, urine, feces and expired air are collected for 96h after dosing.

If 14C-radioactivity quick counts show that radioactivity in urine or feces is above acceptable limits (ie. > 50 dpm/ml in urine; >75 dpm in 400 mg feces) on day 5, subjects are requested to stay in the clinic until the levels decrease. If, after 3 days, radioactivity is still > 50 dpm/ml in urine and/or >75 dpm in 400 mg feces, urine and/or feces is collected at home, until the amount of radioactivity decreases.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 4 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Basic Science
• Official Title: An Open-label Study to Evaluate the Pharmacokinetics of YM178 After Single Oral Administration of 14C-labeled YM178 in Healthy Male Volunteers
• Study Start Date: January 2003
• Actual Primary Completion Date: February 2003
• Actual Study Completion Date: February 2003

Arms and Interventions

Arm	Intervention/treatment
Experimental: 14C-labeled YM178; Single oral administration of 14C-labeled YM178	Drug: 14C-labeled YM178; oral solution (1.85 MBq); Other Names: mirabegron; Myrebtriq

Outcome Measures

Primary Outcome Measures :

1. The assessment of pharmacokinetic profile of radioactivity after single-dose administration of 14C-YM178, measured by whole blood and plasma concentration [ Time Frame: Baseline to Day 5 (optional (Day 6-8) [maximum of 19 assessments] ]
   Cmax, tmax, AUC0-last, AUC0-inf, t1/2 and the blood-to-plasma ratio (Ratio Cb/p)
2. The excretion rate and cumulative excretion of radioactivity in urine, feces and expired air after single-dose administration of 14C-YM178 [ Time Frame: Baseline to Day 5 (optional (Day 6-8) [maximum of 10 assessments] ]
3. The assessment of pharmacokinetic profile of parent YM178 after single-dose administration of 14C-YM178, measured plasma and urine concentration [ Time Frame: Baseline to Day 5 (optional (Day 6-8) [maximum of 19 assessments] ]
   plasma (Cmax, tmax, AUC0-last, AUC0-inf, t1/2 and Vz/F), urine (Ae0-24, Ae0-last, CLR and % dose excreted)

Secondary Outcome Measures :

1. Safety assessed through Adverse Events, vital signs, laboratory analyses and ECG (electrocardiogram) [ Time Frame: Through to Day 19 ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 55 Years (Adult)
• Sexes Eligible for Study: Male
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

• Body weight between 60 and 100 kg, and BMI ≤30 kg/m2

Exclusion Criteria:

• Known or suspected hypersensitivity to β-adrenergic receptor agonists or constituents of the formulations used
• Any clinically significant history of asthma, eczema, any other allergic condition or previous severe hypersensitivity to any drug
• Any clinically significant history of upper gastrointestinal symptoms (such as nausea, vomiting, abdominal discomfort or upset, or heartburn) in the 4 weeks prior to admission to the Research Unit
• Any clinically significant history of any other disease or disorder - gastrointestinal, cardiovascular, respiratory, renal, hepatic, neurological, dermatological, psychiatric or metabolic
• Abnormal pulse rate measurement (<40 or >90 bpm) taken by manual counting at the pre-study visit after subject has been resting in supine position for 5 min

• Abnormal blood pressure measurements taken at the pre-study visit after subject has been resting in supine position for 5 min as follows:

  • Systolic blood pressure <95 or >160 mmHg;
  • Diastolic blood pressure <40 or >95 mmHg.
• Positive orthostatic test at screening i.e. any symptoms of dizziness, light-headedness etc. and/or a fall of ≥ 20 mmHg in systolic blood pressure after 2 min standing (preceded by 5 min. supine rest) and/or an increase in pulse rate of ≥ 20 bpm
• Regular use of any prescribed or OTC (over the counter) drugs except paracetamol up to 3 g/day, in the 4 weeks prior to admission to the Research Unit OR any use of such drugs in the 2 weeks prior to admission to the Research Unit
• History of drug abuse at any time, OR any use of drugs of abuse within 3 months prior to admission to the Research Unit
• History of smoking more than 10 cigarettes (or equivalent amount of tobacco) per day within 3 months prior to admission to the Research Unit
• History of drinking more than 21 units of alcohol per week (1 unit = 270 cc of beer or 40 cc of spirits or 1 glass of wine) within 3 months prior to admission to the Research Unit
• Donation of blood or blood products within 3 months prior to admission to the Research Unit
• Positive serology test for HBsAg, HAV IgM, anti-HCV or anti-HIV 1+2.
• Participation in any clinical study within 3 months, or participation in more than 3 clinical studies within 12 months, prior to the expected date of enrolment into the study
• Subjects having received YM178 previously
• Exposure to radiation for diagnostic reasons (except dental X-rays and plain X-rays of thorax and bony skeleton (excluding spinal column)), during work or during participation in a clinical trial in the previous year

Contacts and Locations

Locations

Netherlands

Pharma Bio-Research Group B.V.

Zuidlaren, Netherlands, 9471 GP

Sponsors and Collaborators

Astellas Pharma Europe B.V.

Investigators

• Study Chair: Clinical Study Manager; Astellas Pharma Europe B.V.

More Information

Additional Information:

Link to Results on JAPIC 

Publications:

Takusagawa S, van Lier JJ, Suzuki K, Nagata M, Meijer J, Krauwinkel W, Schaddelee M, Sekiguchi M, Miyashita A, Iwatsubo T, van Gelderen M, Usui T. Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers. Drug Metab Dispos. 2012 Apr;40(4):815-24. doi: 10.1124/dmd.111.043588. Epub 2012 Jan 23.

• Responsible Party: Astellas Pharma Europe B.V.
• ClinicalTrials.gov Identifier: NCT01651312
• Other Study ID Numbers: 178-CL-007
• First Posted: July 27, 2012
• Last Update Posted: September 5, 2013
• Last Verified: September 2013

Keywords provided by Astellas Pharma Inc ( Astellas Pharma Europe B.V. ):

Radioactivity; Excretion rate; Human subjects; Pharmacokinetics; YM178; Radio-labeled; Phase 1

Additional relevant MeSH terms:

Mirabegron; Adrenergic beta-3 Receptor Agonists; Adrenergic beta-Agonists; Adrenergic Agonists; Adrenergic Agents; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Physiological Effects of Drugs; Urological Agents